Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 119 participants.
Also called NCT05613426
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 119 participants
- Registry
-
NCT05613426
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Terminated
Technical summary
Registry record NCT05613426. Randomized; single masking; primary purpose treatment. Start 2023-04-03 (actual); primary completion 2025-07-16 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI
- Acronym
- EVALUATE-STEMI
- Condition
- ST Elevation Myocardial Infarction (STEMI)
- Intervention (Drug)
- Rosuvastatin 20 mg
- Intervention (Drug)
- Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]
- Lead sponsor
- Henan Institute of Cardiovascular Epidemiology
Record details
- Record id
cardio:ct-nct05613426- Content hash
0165a4792f2dd5d9d20169b1b455602b82604b10e6bcfa968191f53cba11618f